This Week in Medicine: Lp(a) drug fails to protect the heart and more (Week 46, 2026)

Anatomisches Herzmodell vor blauem Hintergrund

A drug that lowers an inherited risk marker in the blood by almost four fifths, yet prevents not a single heart attack: the results of the Lp(a)HORIZON trial shaped the week. There were also new recommendations from the EU medicines regulator, a large trial on knee pain, new Ebola figures and more flu in Germany.

In short: pelacarsen sharply lowered lipoprotein(a) but did not protect against cardiovascular events. The EMA recommends seven new medicines, including a new blood pressure drug. The Ebola outbreak in the DR Congo now counts more than 11,000 confirmed cases, and in Germany flu and COVID-19 reports are slowly rising.

1. Lp(a)HORIZON: Strong reduction, no protection for the heart

What happened? The full results of the Lp(a)HORIZON trial were presented at the American Heart Association congress on 7 November and published in the New England Journal of Medicine. Around 8,300 people with cardiovascular disease and markedly raised lipoprotein(a) received monthly injections of pelacarsen or a placebo for a median of 4.7 years. After one year, lipoprotein(a) had fallen by about 78 percent, compared with about 3 percent on placebo. Yet heart attack, stroke, cardiovascular death or urgent procedures on the coronary arteries occurred equally often: in 12.3 versus 12.1 percent. The manufacturer Novartis has stopped development for this use.

What does it mean? A better lab value does not automatically mean fewer heart attacks – whether other Lp(a)-lowering drugs in ongoing trials do better remains open. Background on hardening of the arteries in our encyclopedia: Atherosclerosis; see also our article Rosuvastatin plus ezetimibe: intensive cholesterol lowering shrinks coronary plaque.

2. EMA: Seven new medicines recommended

What happened? At its meeting from 9 to 12 November, the EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended seven new medicines for approval. They include baxdrostat for adults whose high blood pressure is not adequately controlled despite treatment, and two medicines for lung cancer. Eleven already approved medicines are to receive new indications, for example the antibody obinutuzumab for systemic lupus erythematosus. For the diabetes and weight-loss drug tirzepatide (Mounjaro), the EMA points out that the contraceptive pill may be less reliable during the first four weeks and after each dose increase.

What does it mean? The final approval is granted by the European Commission, usually within a few weeks. Which readings count as too high is shown in our blood pressure chart.

3. Retatrutide: Less knee pain in osteoarthritis

What happened? Two phase 3 trials in the New England Journal of Medicine with more than 1,000 participants in total show that people with obesity and knee osteoarthritis lost around 18 to 25 percent of their body weight on the not-yet-approved drug retatrutide and had clearly less knee pain than on placebo. Gastrointestinal side effects were common, and more participants stopped treatment at higher doses. The trials were randomised and placebo-controlled and funded by the manufacturer.

What does it mean? Whether the drug also protects cartilage was not studied. All the details: Retatrutide for knee osteoarthritis.

4. Ebola: More than 11,000 confirmed cases

What happened? According to the European Centre for Disease Prevention and Control (ECDC), the DR Congo had recorded 11,197 confirmed cases caused by Bundibugyo virus by 12 November, including 5,471 deaths. Ituri province is the most affected. Kenya still has nine cases; the last one was reported on 20 October. There is still no licensed vaccine or specific treatment for this virus species, though several candidates are being tested.

What does it mean? For people living in the EU, the ECDC continues to rate the risk as very low. More about the disease in our encyclopedia: Ebola virus disease.

5. Germany: Flu and COVID-19 slowly increasing

What happened? According to the Robert Koch Institute’s weekly report of 12 November, Germany saw around 5.5 million new acute respiratory illnesses in the week from 2 to 8 November, more than in the previous week. Rhinoviruses and enteroviruses still dominate. Reported flu cases rose to 844 (previous week 726), with influenza A(H1N1) predominant. COVID-19 reports are also rising but remain well below last year’s level; RSV stays low.

What does it mean? Cold season is in full swing and the flu is picking up. Why cold weather alone does not make you ill is explained in our Myth check: Does cold weather make you sick?; the basics of COVID-19 are in our encyclopedia.

Our term of the week: Insulin

14 November was World Diabetes Day. According to diabetesDE – Deutsche Diabetes-Hilfe, around 11 million people in Germany have diabetes, including undiagnosed cases. At the centre is one hormone: insulin, which moves sugar from the blood into the cells. How it works and when it has to be injected: Insulin in the Medical Encyclopedia.

Quiz question of the week

Which organ produces the hormone insulin? A) the liver, B) the pancreas, C) the thyroid gland.

Answer: B is correct. Insulin is made in the beta cells of the pancreas. More practice questions are waiting in the Medical Quiz.

Note: This weekly review is general information and does not replace medical advice. Figures reflect the cited sources from 7 to 13 November 2026 and may change. Pelacarsen and retatrutide are not approved.

Sources

AnzeigeAnzeige: WUNDREPAIR – Pflege aus Pflanzen

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.